Table 1 Demographics, disease characteristics and medication of the study group

Female sex (%)

13 (41)

Age, y (median, range)

66 (37-83)

BMI (mean, SD)

24 (3.7)

Smoker (%)

7 (22)

History of diabetes (%)

12 (38)

History of cardiovascular disease (%)

19 (59)

History of myocardial infarction (%)

6 (19)

Dialysis vintage, month (median, IQR)

10 (6 - 30)

Dialysis modality (PD/HD) (%)

50/50

 Diabetic nephropathy (%)

11 (34)

 Hypertension/Arteriosclerosis (%)

4 (13)

 Polycystic kidney disease (%)

7 (22)

 Glomerulonephritis (%)

6 (19)

 Other/unknown (%)

4 (13)

 fS-calcium-ion 1.16 mmol/l - 1.30 mmol/l (mean, SD))

1.17 (0.08)

 fP-phosphorus 0.71 – 1.23 mmol/l (median, IQR)

1.68 (0.48)

 fP-iPTH 15 – 65 ng/l (median, IQR)

319 (188 – 508)

 P- D-25 > 50 nmol/l (median, IQR)

70 (49 – 95)

 S- D- 1,25 37 – 216 pmol/l (median, IQR)

31 (24 – 52)

 P-tALP 35 – 105 U/l (median, IQR)

84 (57 – 128)

 P-Albumine 36 – 45 g/l (median, IQR)

32 (28 – 34)

 P-Magnesium 0.7 – 1 mmol/l (median, IQR)

0.9 (0.7 – 1.0)

 cB-HCO3 22 – 26 mmol/l (median, IQR)

24 (22 – 26)

 High turnover/hyperparathyreoid bone disease (%)

11 (39)

 Normal turnover/mild hyperparathyroid bone disease (%)

11 (39)

 Low turnover/adynamic bone disease (%)

6 (22)

 Lumbar spine, K_{i mean} L1-L4 (median, range)

0.040 (0.023 – 0.093)

 Anterior iliac creast, FUR_mean hip (median, range)

0.041 (0.025 – 0.081)

 T-score L1-L4 (mean, SD)

−1.06 (1.58)

 T-score femoral neck (mean, SD)

−2.0 (1.0)

Osteoporosis (T-score ≤ −2.5) (%)

10 (33)

AAC score (median, range)

8 (0 - 17)

CAC score (median, range)

397 (0 – 1980)

 Calcimimetic (%)

5 (16)

 Alfacalcidol, Paricalcitol (%)

21 (66)

 Calcium carbonate (%)

28 (88)

 Cholecalciferol (%)

29 (91)

 Sevelamer/lantane carbonate (%)

18 (56)

 Corticosteroid (%)

2 (6)